Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequen...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1412 |
id |
doaj-ab9b0fc37e214f8b9c9965cfdfb84607 |
---|---|
record_format |
Article |
spelling |
doaj-ab9b0fc37e214f8b9c9965cfdfb846072020-11-25T01:36:05ZengMDPI AGCancers2072-66942019-09-011110141210.3390/cancers11101412cancers11101412Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future ApplicationsRiccardo Laudicella0Domenico Albano1Salvatore Annunziata2Diletta Calabrò3Giovanni Argiroffi4Elisabetta Abenavoli5Flavia Linguanti6Domenico Albano7Antonio Vento8Antonio Bruno9Pierpaolo Alongi10Matteo Bauckneht11Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, ItalyDepartment of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, ItalyInstitute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyNuclear Medicine, DIMES University of Bologna, S. Orsola-Malpighi Hospital, 40138 Bologna, ItalyDepartment of Health Sciences, University of Milan, 20142 Milan, ItalyNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50134 Florence, ItalyNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50134 Florence, ItalyIRCCS Istituto Ortopedico Galeazzi, Unità di Radiologia Diagnostica ed Interventistica, 20161 Milano, ItalyDepartment of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, S. Orsola-Malpighi Hospital, 40138 Bologna, ItalyUnit of Nuclear Medicine, Fondazione Istituto G. Giglio, 90015 Cefalù, ItalyNuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyMeningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma.https://www.mdpi.com/2072-6694/11/10/1412meningiomasomatostatin receptorneuroimagingpositron emission tomographyradionuclide therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Riccardo Laudicella Domenico Albano Salvatore Annunziata Diletta Calabrò Giovanni Argiroffi Elisabetta Abenavoli Flavia Linguanti Domenico Albano Antonio Vento Antonio Bruno Pierpaolo Alongi Matteo Bauckneht |
spellingShingle |
Riccardo Laudicella Domenico Albano Salvatore Annunziata Diletta Calabrò Giovanni Argiroffi Elisabetta Abenavoli Flavia Linguanti Domenico Albano Antonio Vento Antonio Bruno Pierpaolo Alongi Matteo Bauckneht Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications Cancers meningioma somatostatin receptor neuroimaging positron emission tomography radionuclide therapy |
author_facet |
Riccardo Laudicella Domenico Albano Salvatore Annunziata Diletta Calabrò Giovanni Argiroffi Elisabetta Abenavoli Flavia Linguanti Domenico Albano Antonio Vento Antonio Bruno Pierpaolo Alongi Matteo Bauckneht |
author_sort |
Riccardo Laudicella |
title |
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_short |
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_full |
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_fullStr |
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_full_unstemmed |
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_sort |
theragnostic use of radiolabelled dota-peptides in meningioma: from clinical demand to future applications |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-09-01 |
description |
Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma. |
topic |
meningioma somatostatin receptor neuroimaging positron emission tomography radionuclide therapy |
url |
https://www.mdpi.com/2072-6694/11/10/1412 |
work_keys_str_mv |
AT riccardolaudicella theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT domenicoalbano theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT salvatoreannunziata theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT dilettacalabro theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT giovanniargiroffi theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT elisabettaabenavoli theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT flavialinguanti theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT domenicoalbano theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT antoniovento theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT antoniobruno theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT pierpaoloalongi theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT matteobauckneht theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications |
_version_ |
1725064350258954240 |